For research use only. Not for therapeutic Use.
MMAF intermediate 2 is an intermediate for the synthesis of MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent inhibitor of tubulin polymerization and the cytotoxic (ADC Cytotoxin) component of classic antibody drug conjugates (ADCs), such as Vorsetuzumab mafodotin and SGN-CD19A[1].
| Catalog Number | I040440 |
| CAS Number | 864238-20-0 |
| Synonyms | methyl (2S)-2-[[(2R,3R)-3-methoxy-2-methyl-3-[(2S)-pyrrolidin-2-yl]propanoyl]amino]-3-phenylpropanoate;hydrochloride |
| Molecular Formula | C19H29ClN2O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C19H28N2O4.ClH/c1-13(17(24-2)15-10-7-11-20-15)18(22)21-16(19(23)25-3)12-14-8-5-4-6-9-14;/h4-6,8-9,13,15-17,20H,7,10-12H2,1-3H3,(H,21,22);1H/t13-,15+,16+,17-;/m1./s1 |
| InChIKey | IKNWSNCMBMHJAU-WOLLCHHQSA-N |
| SMILES | CC(C(C1CCCN1)OC)C(=O)NC(CC2=CC=CC=C2)C(=O)OC.Cl |
| Reference | [1]. Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16(9):2562-70. [Content Brief] |
